Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
about
Regression toward the mean--a detection method for unknown population mean based on Mee and Chua's algorithm.Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: complex congenital cardiac lesions.Perioperative pharmacological management of pulmonary hypertensive crisis during congenital heart surgeryAdult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentanExercise testing and prescription in patients with congenital heart disease.Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effectLong-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.Applicability of bosentan in Dutch patients with Eisenmenger syndrome: preliminary results on safety and exercise capacity.Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects.An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease.Endothelin receptor antagonist therapy in congenital heart disease with shunt-associated pulmonary arterial hypertension: a qualitative systematic reviewImpact of pulmonary vascular resistances in heart transplantation for congenital heart disease.The challenge of managing pulmonary arterial hypertension in adults with congenital heart disease.The Effect of Endothelin Receptor Antagonists in Patients with Eisenmenger Syndrome: A Systematic Review.The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part II: Medical Treatment - Study Results.Pulmonary arterial hypertension associated with congenital heart disease: the efficacy of drug treatment in symptomatic patients.Bosentan in pulmonary arterial hypertension: a comparison between congenital heart disease and chronic pulmonary embolism.Prostacyclin-analog therapy in sickle cell pulmonary hypertension.Advanced therapies for the management of adults with pulmonary arterial hypertension due to congenital heart disease: a systematic review.Bosentan in Eisenmenger syndrome and chronic thromboembolic pulmonary hypertension.Adult congenital heart disease and pulmonary arterial hypertension: the Texas Adult Congenital Heart Program experience.Pulmonary arterial hypertension associated with a congenital heart defect: advanced medium-term medical treatment stabilizes clinical condition.The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: A systematic review and meta-analysis.
P2860
Q33358555-4B9CFDF7-9BF1-42C2-9DB7-0A6864A3F09BQ33776432-E7F4BA97-7613-433F-9C01-EFA4CD12EC87Q33805945-BBB69D5E-A9D6-47B2-B61A-82C9B58B0D1DQ34133301-FD4867DA-38D9-4DA7-BC5B-100803A04A36Q34143576-7592EDCA-13FB-440B-9BA7-93755240D771Q35773295-A1FB56EE-2119-4327-93A1-0848A9948EFEQ35956167-2DA92368-F539-4B77-99B8-D1B4F39A9F4BQ36014079-C3164373-3285-486F-9705-0085E3918D32Q36917342-179DCB9E-5ACB-41EA-B88F-FFD08C80D841Q36932136-7E9F0ACD-A04F-4720-97D1-F7C88A35DC41Q37195331-3A36F77A-D123-42E1-8DB0-DF2A409D5C0EQ37215048-959E45A7-0844-4E9F-9DC0-A449F5F4D9B8Q38006697-048B574A-5EBF-4A62-879A-BC799200D28BQ38124878-A82FBABA-D1F9-4C11-8E54-1E2B6F67BF26Q38992606-536C23A5-BBA8-4EF1-B685-C6DF25AF3AA3Q41852030-09DBCBEC-5CBE-4523-95DF-DE83B77BA540Q41948962-832583F5-BE91-42B2-B66A-070B51391BD3Q42284467-03B74BA2-2827-4E85-B27F-930F49B2C958Q42336345-9543B0B2-20ED-4473-9140-301544FBEF65Q47561539-C8E0F452-809A-4560-91A0-762A82BB2C51Q50724533-E1D599F0-1DC1-446D-8F3A-6A4283561F68Q51493465-A078E36C-1DEF-4E85-8194-03D1BF928826Q51708721-F6AFE4DF-4DC6-488A-A2FB-6762593B672DQ53703751-12F6553D-4FAE-4AB8-93DD-7411FE00FDF3
P2860
Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Effect of the oral endothelin ...... d to congenital heart disease.
@ast
Effect of the oral endothelin ...... d to congenital heart disease.
@en
type
label
Effect of the oral endothelin ...... d to congenital heart disease.
@ast
Effect of the oral endothelin ...... d to congenital heart disease.
@en
prefLabel
Effect of the oral endothelin ...... d to congenital heart disease.
@ast
Effect of the oral endothelin ...... d to congenital heart disease.
@en
P2093
P2860
P356
P1433
P1476
Effect of the oral endothelin ...... d to congenital heart disease.
@en
P2093
A Manginas
D V Cokkinos
S C Apostolopoulou
P2860
P304
P356
10.1136/HRT.2004.051961
P407
P577
2005-03-10T00:00:00Z